|
Jimenez-Coll V, El Kaaoui El Band J, Llorente S, Gonzalez-Lopez R, Fernandez-Gonzalez M, Martinez-Banaclocha H, Galian JA, Botella C, Moya-Quiles MR, Minguela A, Legaz I, Muro M. All That Glitters in cfDNA Analysis Is Not Gold or Its Utility Is Completely Established Due to Graft Damage: A Critical Review in the Field of Transplantation. Diagnostics (Basel). 2023 Jun 6;13(12):1982. doi: 10.3390/diagnostics13121982. PubMed PMID: 37370877; PubMed Central PMCID: PMC10297394.
AÑO: 2023; IF: 3.0
|
37370877
|
Alfaro R, Rodriguez-Aguilar L, Llorente S, Jimenez-Coll V, Martinez-Banaclocha H, Galian JA, Botella C, Moya-Quiles MR, Muro-Perez M, Minguela A, Legaz I, Muro M. Early Cytomegalovirus Reactivation in Renal Recipients Is Associated with High Levels of B Cell Maturation Antigen Transcript Expression Prior to Transplantation. Int J Mol Sci. 2023 Jun 22;24(13):10491. doi: 10.3390/ijms241310491. PubMed PMID: 37445668; PubMed Central PMCID: PMC10341624.
AÑO: 2023; IF: 4.9
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2024 Jan;26(1):278-287. doi: 10.1007/s12094-023-03251-0. Epub 2023 Jun 27. PubMed PMID: 37368200.
AÑO: 2024; IF: 2.8
|
|
Cuenca I, Botella C, Moya-Quiles MR, Jimenez-Coll V, Galian JA, Martinez-Banaclocha H, Muro-Perez M, Minguela A, Legaz I, Muro M. Genotypic Frequencies of Mutations Associated with Alpha-1 Antitrypsin Deficiency in Unrelated Bone Marrow Donors from the Murcia Region Donor Registry in the Southeast of Spain. Diagnostics (Basel). 2023 Sep 2;13(17):2845. doi: 10.3390/diagnostics13172845. PubMed PMID: 37685383; PubMed Central PMCID: PMC10486455.
AÑO: 2023; IF: 3.0
|
|
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408; PubMed Central PMCID: PMC10772462.
AÑO: 2023; IF: 11.7
|